Home > Recommended

OEM/ODM for White Powder Tetracaine Hcl Intermediate Iguratimod intermediate cas 149436-41-9 cas 149457-03-4 export to Australia Suppliers

Share to:  
  • Product Detail
  • Product Tags
  • Buyer Reviews

We strive for excellence, services the customers", hopes to be the top cooperation team and dominator business for personnel, suppliers and prospects, realizes benefit share and continual promotion for Iguratimod Cas 123663-49-0 99% Powder,Rheumatoid Arthritis Pharmaceutical,T 614 Api Antirheumatic Drug. We have now a hugely efficient team to deal with inquiries from buyers. Our goal is "100% client gratification by our solution high-quality, rate & our team service" and take pleasure in a great popularity among clients. With several factories, we will provide a wide assortment of

OEM/ODM for White Powder Tetracaine Hcl Intermediate Iguratimod intermediate cas 149436-41-9 cas 149457-03-4 export to Australia Suppliers

Chemical Name:

N-(4-(2-aminoacetyl)-5-methoxy-2-phenoxyphenyl)methanesulfonamide hydrochloride

Molecular Formula: C16H19ClN2O5S

Formula Weight: 386.85

CAS No.: 149436-41-9


Chemical Name: MethanesulfonaMide, N-[4-[2-(forMylaMino)acetyl]-5-hydroxy-2-phenoxyphenyl]-

Molecular Formula: C17H18N2O6S

Formula Weight: 378.39962

CAS No.: 149457-03-4


Chemical Name: Iguratimod

Molecular Formula: C17H14N2O6S

Formula Weight: 374.37

CAS No.: 123663-49-0


Iguratimod is an anti-inflammatory small molecule drug used for the treatment of rheumatoid arthritis, together with methotrexate in Japan and China. As of 2015 the biological target was not known, but it prevents NF-κB activation and subsequently selectively inhibits COX-2 and several inflammatory cytokines.


Iguratimod is under investigation in Rheumatoid Arthritis.

Iguratimod, a methanesulfonanilide, is a novel disease-modifying antirheumatic drug that has been developed exclusively in Japan and China. It inhibits the production of immunoglobulins and various inflammatory cytokines (interleukin-1, -6 and -8 and TNF), and exerts anabolic effects on bone metabolism by stimulating osteoblastic differentiation and inhibiting osteoclastogenesis. On the molecular level, it inhibits the nuclear transcription factor NF-κB but not its inhibitor, IκBα. In addition to these immunomodulatory and other long-lasting effects, iguratimod inhibits cyclooxygenase-2, which provides a synergistic short-term action against pain and inflammation. Efficacy and tolerability are comparable to salazosulfapyridine, and probably also to methotrexate. Combination with methotrexate is synergistic in patients with insufficient response to methotrexate and does not significantly increase adverse events. Liver enzyme elevations and thrombocytopenia are the most significant side effects to watch for. In summary, iguratimod is a welcome addition to the small-molecule drug therapy of rheumatoid arthritis.


"Using a complete scientific top quality management program, great high-quality and fantastic religion, we win great track record and occupied this area for Iguratimod intermediate cas 149436-41-9 cas 149457-03-4. The product will supply to all over the world, such as: Papua New Guinea,Estonia,Luxembourg. Our company warmly invites domestic and overseas customers to come and negotiate business with us. Allow us to join hands to create a brilliant tomorrow! We are looking forward to cooperating with you sincerely to achieve a win-win situation. We promise to try our best to deliver you with high quality and efficient services.

Email To This Supplier

Your message must be between 20-8000 characters


Communicate with Supplier?Supplier
Mr. Vid Mr. Mr. Vid
What can I do for you?
Contact Supplier